HLX43 targets PD-L1, is internalized, and releases a camptothecin-based topoisomerase I inhibitor that induces DNA damage and apoptosis in PD-L1–positive (and some bystander) cells. DNA topoisomerase I is the intracellular payload target, not the cell-surface antigen used for targeting.